Evidence map›Paper›PMID 42306037›Full record

ArticleACG case reports journal2026

Infliximab-Responsive Severe Ulcerative Colitis With Pyoderma Gangrenosum After IL-6 and IGF-1 Blockade.

Shinobu Onishi, Shinsuke Otagiri, Akihiro Shinkai, Mika Watanabe, Sho Tanaka, Kenta Fujihata, Keiya Aoyama, Ayano Inoue, Takehiko Katsurada, Naoya Sakamoto

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in ACG case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shinobu OnishiSchool of Medicine, Hokkaido University, Sapporo, Japan.
Shinsuke OtagiriDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan.ORCID https://orcid.org/0000-0002-2209-9334
Akihiro ShinkaiDepartment of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Mika WatanabeDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan.
Sho TanakaDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan.
Kenta FujihataDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan.
Keiya AoyamaDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan.
Ayano InoueDepartment of Diagnostic Pathology, Sapporo City General Hospital, Sapporo, Japan.
Takehiko KatsuradaDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan.
Naoya SakamotoDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interleukin-6 (IL-6) and insulin-like growth factor-1 (IGF-1) are involved in immune regulation and tissue repair, but their combined effects on gastrointestinal mucosa remain unclear. We report a case of new-onset ulcerative colitis with pyoderma gangrenosum after sequential IL-6 and IGF-1 receptor inhibition. The patient developed severe ulcerative colitis and pyoderma gangrenosum refractory to corticosteroids but showed rapid improvement after infliximab therapy, with endoscopic evidence of mucosal improvement. This case highlights a potential role for tumor necrosis factor-α (TNF-α) blockade in reversing severe immune dysregulation induced by IL-6 and IGF-1 inhibition.

Indexed as

infliximabinsulin-like growth factor-1interleukin-6pyoderma gangrenosumulcerative colitis

Identifiers

PMID42306037
PMCPMC13268424

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.